Log In
BCIQ
Print this Print this
 

BI1147560

  Manage Alerts
Collapse Summary General Information
Company Allergan plc
DescriptionBeta-site APP-cleaving enzyme inhibitor
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat Alzheimer's disease (AD)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$639.0M

$639.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/25/2016

$639.0M

$639.0M

0

Get a free BioCentury trial today